151096-09-2
基本信息
莫西沙星
(4ΑS-CIS)-1-环丙基-6-氟-1,4-二氢-8-甲氧基-7-(六氢-6H-吡咯[3,4-B] 吡啶-6-基)-4-氧-3-喹啉羧酸
(1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
MAXIOFFOXACIN
(4αS-cis)-1-Cydopropyl-6-fluoro-1，4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolo[3，4-b]pyridin-6-y1)-4-oxo-3-quinolinecarboxylic acid
Avdox
物理化学性质
| 熔点 | 203-208 C |
| 比旋光度 | 23D -193° |
| 沸点 | 636.4±55.0 °C(Predicted) |
| 密度 | 1.408±0.06 g/cm3(Predicted) |
| 储存条件 | Keep in dark place,Sealed in dry,2-8°C |
| 溶解度 | 乙腈（微溶）、DMSO（微溶、加热、超声处理）、甲醇（微溶） |
| 酸度系数(pKa) | 6.43±0.50(Predicted) |
| 形态 | 固体 |
| 颜色 | 灰白色至淡黄色 |
| 稳定性 | 吸湿性 |
| InChIKey | FABPRXSRWADJSP-MEDUHNTESA-N |
| SMILES | N1(C2CC2)C2=C(C=C(F)C(N3C[C@]4([H])CCCN[C@]4([H])C3)=C2OC)C(=O)C(C(O)=O)=C1 |
| CAS 数据库 | 151096-09-2(CAS DataBase Reference) |
| EPA化学物质信息 | 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (151096-09-2) |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H319-H302-H412 |
| 防范说明 | P273-P501-P264-P280-P305+P351+P338-P337+P313P-P264-P270-P301+P312-P330-P501 |
| 危险品标志 | Xn |
| 危险类别码 | 22-40 |
| 安全说明 | 36/37 |
| 毒害物质数据 | 151096-09-2(Hazardous Substances Data) |
应用领域
制备方法
常见问题列表
莫西沙星最常见的不良反应包括：恶心、腹泻、头痛和头晕以及心脏Q-T间期延长。
较少见的不良反应，包括全身反应（如过敏反应等）、心血管系统反应（如高血压、心悸）、消化系统反应（如腹痛、厌食、便秘、消化不良等）、骨骼肌肉系统反应（如关节痛、肌肉痛）、神经系统反应（如激动、焦虑、失眠、紧张、感觉异常等）、呼吸系统反应（如呼吸困难）、皮肤软组织系统反应（如瘙痒、皮疹、多汗等）。
此外，莫西沙星还可能导致部分实验室检验异常，如中性粒细胞减少，碱性磷酸酶、血清尿素氮、血清肌酐升高等。
1）如果口服莫西沙星，请固定在每天同一时间服药，餐前餐后均可；如果静脉滴注莫西沙星，请至少滴注90分钟；
2）用药后接触阳光或紫外线，可能引起严重的光过敏，出现过度晒伤的症状，所以用药期间请采取防晒措施；
3）莫西沙星可能引起头晕等情况，用药期间尽量避免驾驶等危险行为；
4）用药后可能会干扰血糖，如果糖尿病患者使用，请注意监测血糖；
用药后可能引发严重副作用，如肌腱炎、肌腱断裂、周围神经病变及中枢神经系统副作用，或加重重症肌无力，如果出现以上副作用，请停药并联系医师，避免再次用药。
Bacterial
The in vitro activities of Moxifloxacin and Amoxicillin are compared by time-kill curve and inhibition of intracellular growth experiments by using a model of bone marrow-derived mouse macrophages infected by L. monocytogenes EGDe. Moxifloxacin acts much more rapidly, beginning to exert its effects in the first 3 h and achieving complete broth sterilization within 24 h of incubation. Moxifloxacin appears to have a protective effect against macrophage lysis, as many cells are still viable after 24 h of incubation.
Moxifloxacin (12 mg/kg; intravenous injection; once-three times per day; for 7 days; white male Wistar rats) treatment every 8 hours is accompanied by longer survival. Tissue cultures 30 hours after bacterial challenge shows considerably less bacterial overgrowth in the spleens and lungs of moxifloxacin-treated than in salinetreated animals and without being toxic.
| Animal Model: | 144 white male Wistar rats (18-22 weeks; 300-400 g) infected Stenotrophomonas maltophilia |
| Dosage: | 12 mg/kg |
| Administration: | Intravenous injection; once per day, twice per day, three times per day; for 7 days |
| Result: | Showed considerably less bacterial overgrowth in the spleens and lungs and without being toxic. |
莫西沙星价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/09/19 | S5535 | 莫西沙星 Moxifloxacin | 151096-09-2 | 25mg | 794.9元 |
| 2025/05/22 | HY-66011A | 莫西沙星 Moxifloxacin | 151096-09-2 | 100mg | 500元 |
| 2025/05/22 | XW1510960922 | 莫西沙星 | 151096-09-2 | 1G | 218元 |